Simon Bornschein

Leuven, VLG, Belgium

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 14 publications

Correction: Mutant JAK3 phosphoproteomic profiling predicts synergism between JAK3 inhibitors and MEK/BCL2 inhibitors for the treatment of T-cell acute lymphoblastic leukemia.

Correction: Mutant JAK3 phosphoproteomic profiling predicts synergism between JAK3 inhibitors and MEK/BCL2 inhibitors for the treatment of T-cell acute lymphoblastic leukemia.

Journal: Leukemia

Published: September 21, 2018

A comprehensive inventory of TLX1 controlled long non-coding RNAs in T-cell acute lymphoblastic leukemia through polyA+ and total RNA sequencing.

A comprehensive inventory of TLX1 controlled long non-coding RNAs in T-cell acute lymphoblastic leukemia through polyA+ and total RNA sequencing.

Journal: Haematologica

Published: June 30, 2018

The Long Non-coding RNA Flatr Anticipates Foxp3 Expression in Regulatory T Cells.

The Long Non-coding RNA Flatr Anticipates Foxp3 Expression in Regulatory T Cells.

Journal: Frontiers in immunology

Published: April 30, 2018

Targeted editing of the PSIP1 gene encoding LEDGF/p75 protects cells against HIV infection.

Targeted editing of the PSIP1 gene encoding LEDGF/p75 protects cells against HIV infection.

Journal: Scientific reports

Published: March 20, 2018

Malt1 self-cleavage is critical for regulatory T cell homeostasis and anti-tumor immunity in mice.

Malt1 self-cleavage is critical for regulatory T cell homeostasis and anti-tumor immunity in mice.

Journal: European journal of immunology

Published: March 13, 2018

Cooperative Enhancer Activation by TLX1 and STAT5 Drives Development of NUP214-ABL1/TLX1-Positive T Cell Acute Lymphoblastic Leukemia.

Cooperative Enhancer Activation by TLX1 and STAT5 Drives Development of NUP214-ABL1/TLX1-Positive T Cell Acute Lymphoblastic Leukemia.

Journal: Cancer cell

Published: August 31, 2017

Mutant JAK3 signaling is increased by loss of wild-type JAK3 or by acquisition of secondary JAK3 mutations in T-ALL.

Mutant JAK3 signaling is increased by loss of wild-type JAK3 or by acquisition of secondary JAK3 mutations in T-ALL.

Journal: Blood

Published: July 20, 2017

Defining the molecular basis of oncogenic cooperation between TAL1 expression and Pten deletion in T-ALL using a novel pro-T-cell model system.

Defining the molecular basis of oncogenic cooperation between TAL1 expression and Pten deletion in T-ALL using a novel pro-T-cell model system.

Journal: Leukemia

Published: July 19, 2017

HOXA9 Cooperates with Activated JAK/STAT Signaling to Drive Leukemia Development.

HOXA9 Cooperates with Activated JAK/STAT Signaling to Drive Leukemia Development.

Journal: Cancer discovery

Published: May 24, 2017

Mutant JAK3 phosphoproteomic profiling predicts synergism between JAK3 inhibitors and MEK/BCL2 inhibitors for the treatment of T-cell acute lymphoblastic leukemia.

Mutant JAK3 phosphoproteomic profiling predicts synergism between JAK3 inhibitors and MEK/BCL2 inhibitors for the treatment of T-cell acute lymphoblastic leukemia.

Journal: Leukemia

Published: March 30, 2017

The T-cell leukemia-associated ribosomal RPL10 R98S mutation enhances JAK-STAT signaling.

The T-cell leukemia-associated ribosomal RPL10 R98S mutation enhances JAK-STAT signaling.

Journal: Leukemia

Published: December 01, 2016

IL-2 consumption by highly activated CD8 T cells induces regulatory T-cell dysfunction in patients with hemophagocytic lymphohistiocytosis.

IL-2 consumption by highly activated CD8 T cells induces regulatory T-cell dysfunction in patients with hemophagocytic lymphohistiocytosis.

Journal: The Journal of allergy and clinical immunology

Published: August 20, 2015

Showing 1-12 of 14

Last Updated: 09/26/2026